Precision Biosciences (DTIL) Net Cash Flow (2018 - 2026)

Precision Biosciences (DTIL) has 9 years of Net Cash Flow data on file, last reported at -$11.3 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 30.27% year-over-year to -$11.3 million in Q1 2026; TTM through Mar 2026 was $26.1 million, a 168.62% increase from a year earlier, with the FY2025 full-year figure at $28.7 million, up 449.39% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$11.3 million, down from $65.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for DTIL reached as high as $67.9 million in Q2 2022 and fell as low as -$31.4 million in Q1 2023.
• Historically, Net Cash Flow has averaged -$1.0 million across 5 years, with a median of -$12.9 million in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 612.76% in 2025 and fell as far as 506.06% in 2025.
• Year by year, Net Cash Flow stood at -$22.5 million in 2022, then jumped by 75.29% to -$5.6 million in 2023, then tumbled by 131.59% to -$12.9 million in 2024, then surged by 612.76% to $65.9 million in 2025, then tumbled by 117.15% to -$11.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$11.3 million in Q1 2026, $65.9 million in Q4 2025, and -$13.6 million in Q3 2025.